VWF and Von Willebrand disease: These results suggest that MICAL1 could represent a promising therapeutic target for pathologies characterized by VWF hyperactivation, such as in patients who have undergone transcatheter aortic valve implantation (TAVI) or those with type 2B von Willebrand disease.